dm+d
Unassigned
New Medicines
Opioid-induced constipation
Information
New molecular entity
Not Known
Cubist
Development and Regulatory status
Discontinued
Discontinued
Discontinued
May 15: Following acquisition of Cubist by Merck (MSD), development for this indication was discontinued [1].
Category
Highly peripheralised opioid mu receptor antagonist
Opioid-induced constipation
Oral